Picture [iito] No Tracking 650x100px
Document › Details

Immatics N.V.. (8/9/22). "Press Release: Immatics Announces Second Quarter 2022 Financial Results and Business Update". Tübingen & Houston, TX.

Organisations Organisation Immatics N.V. (Nasdaq: IMTX)
  Group Immatics (Group)
  Organisation 2 Editas Medicine Inc. (Nasdaq: EDIT)
Products Product IMA203 TCR-T candidate targeting PRAME (ACTengine)
  Product 2 ACTallo® platform (allogeneic gamma delta T cell therapy platform)
Persons Person Singh, Harpreet (Immatics 201907– CEO before CSO + CEO of Immatics US + Co-Founder)
  Person 2 Valente, Nancy (Immatics 202203– Non-executive Board Director formerly at Genentech/Roche)

Record changed: 2022-09-23


Picture [iito] [LSE] Business Portal 650x200px

More documents for Immatics (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] [LSE] Business Portal 650x300px

» top